NGM Bio to Participate in the B. Riley Securities 4th Annual Oncology Conference
January 17 2024 - 4:47PM
NGM Biopharmaceuticals, Inc. (Nasdaq: NGM), a biotechnology company
focused on discovering and developing transformative therapeutics
for patients, today announced that David J. Woodhouse, Ph.D., Chief
Executive Officer, and Jean-Frédéric Viret, Ph.D., Chief Financial
Officer, will participate in the B. Riley Securities 4th Annual
Oncology Conference and will provide a business update focusing on
NGM Bio’s wholly-owned oncology portfolio on Thursday, January
18th, at 2:30 pm ET.
A replay of the presentation will be available under the
Investors and Media section of NGM Bio’s website at
https://ir.ngmbio.com/events-presentations and will be archived on
NGM Bio’s site for at least 30 days following the event.
About NGM Bio
NGM Bio is focused on discovering and developing novel,
life-changing medicines for people whose health and lives have been
disrupted by disease. NGM Bio’s biology-centric drug discovery
approach aims to seamlessly integrate interrogation of complex
disease-associated biology and protein engineering expertise to
unlock proprietary insights that are leveraged to generate
promising product candidates and enable their rapid advancement
into proof-of-concept studies. All therapeutic candidates in the
NGM Bio pipeline have been generated by its in-house discovery
engine, always led by biology and motivated by unmet patient need.
Visit us at www.ngmbio.com for more information.
Investor Contact: |
Media
Contact: |
ir@ngmbio.com |
media@ngmbio.com |
NGM Biopharmaceuticals (NASDAQ:NGM)
Historical Stock Chart
From Nov 2024 to Dec 2024
NGM Biopharmaceuticals (NASDAQ:NGM)
Historical Stock Chart
From Dec 2023 to Dec 2024